Investor
Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 441 (TSX: $AVCN.TO)
(CSE: $IMCC.C) (OTC: $PSYC)
Delta, Kelowna, BC, July 15, 2020 (Investorideas.com Newswire)
www.Investorideas.com, a global news source covering leading sectors including
marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2020/cannabis-potcasts/07151AVCN-IMCC-PSYC.asp
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we look at a few public and private company announcements.
Avicanna Inc. (TSX:
AVCN) (OTCQX:
AVCNF), a biopharmaceutical company focused on the
development, manufacturing and commercialization of plant-derived
cannabinoid-based products announced that
its Rho Phyto™ product line of advanced medical cannabis products will be the
subject of a Medical Cannabis Real-World Evidence study ("MC-RWE
Study") led by Dr. Hance Clarke of the University Health Network
("UHN") in Toronto, Canada. The Rho Phyto products were developed in
accordance with the recent Health Canada Cannabis 2.0 regulations that allow
for more advanced, higher quality, medical cannabis product offerings. These
products have been tested for prolonged stability, enhanced absorption,
controlled delivery and other properties, in collaboration with Dr. Christine
Allen's research group at the Leslie Dan Faculty of Pharmacy, University of
Toronto.
The Rho
Phyto medical cannabis product line is a full formulary that includes
sublingual sprays, oil drops, capsules, and topicals of various cannabinoid
ratios, namely THC and CBD.
By
offering a variety of delivery systems, the medical community has the
possibility to select the appropriate Rho Phyto product to suit a range of
medical conditions such as pain relief, which may require either a fast onset
of action or prolonged duration of effect over the course of treatment. The
products are manufactured under good manufacturing practice ("GMP")
in partnership with MediPharm Labs Inc. to ensure batch-to-batch consistency
and high-quality products. The manufacture of the Rho Phyto products in
accordance with GMP standard allows for data derived from this MC-RWE Study to
provide early insights into Avicanna's ongoing and future directions of
pharmaceutical development. Avicanna remains committed to patient safety and
product consistency which is why all products subject to the MC-RWE Study are
tested by Sigma Analytical and tracked by TruTrace Blockchain Technologies.
Dr.
Justin Grant, Avicanna's Executive Vice President of Scientific Affairs
commented, "After 3 years of collaborating with world-class Toronto-based
researchers and clinicians including those at the University of Toronto and
UHN, we are excited to offer the most consistent formulary of advanced medical
cannabis products to prescribers and principal investigators, including Dr.
Clarke, to further demonstrate the potential therapeutic efficacy of
cannabinoids."
Avicanna's
Rho Phyto products will be exclusively available to patients through the
Medical
Cannabis
by Shoppers online portal in addition to UHN clinicians through the MC-RWE
Study by the end of July 2020. Additionally, Avicanna and Medical Cannabis by
Shoppers are co-hosting a medical symposium in line with the launch of the Rho
Phyto product line entitled, "MEDICAL
CANNABIS 2.0: Advancements in Cannabinoid Research, Product Offerings and
Patient Access". The symposium will be held on a virtual platform on
July 21, 2020 and will include Dr Clarke's presentation "Real World Evidence and The Future of
Medical Cannabis / Cannabinoid medicine for Pain Management" that will
provide further insights on the MC-RWE Study. For registration and more
information please visit (https://www.avicanna.com/symposium/).
The
Health Depot Pharmacy and Lyte
Medical announced their
patient-centered online partnership; a venture that will help Canadians access
medical care and prescriptions from the comfort and safety of their homes.
As Canadians adjust to a new reality
and work to establish new daily routines; consistent access to healthcare and
medications takes on even more importance. Virtual and direct-to-door
prescription delivery are a necessity in meeting patients where they are.
According to the Canadian
Radiotelevision and Telecommunications Commission, nationally, 86% of Canadian
households have access to high speed internet. This online access presents
health care practitioners and pharmacists with an opportunity to connect with
patients remotely and remove some of the barriers to continuity of care including
wait times, transportation, and scheduling.
In February 2020, The Canadian
Medical Association, the Royal College of Physicians and Surgeons of Canada and
the College of Family Physicians of Canada released a report on the future of
virtual care in Canada. They emphasized the importance of prioritizing
quality-based virtual care that truly respects the needs of Canadians.
"As a registered pharmacist
since 2011, I have witnessed the evolution of health care in Canada. The Health
Depot Pharmacy's partnership with Lyte Medical will allow Ontarians to see a
physician and access their prescribed medications in a timely fashion",
says Andy Donald, Founder & CEO of The Health Depot Pharmacy. "Our
unique pharmacy services and approach allows necessary medications to be
delivered promptly to those who rely on them, wherever and whenever they need
them."
The Health Depot makes the pharmacy
and healthcare shopping experience simple for all Ontarians. Their healthcare
e-commerce store has thousands of health essentials available for online
purchase and delivery, which can be shipped together with prescriptions for
free.
Their Daily Dose Packs allow for an
easy approach for patients who are taking multiple medications to have a
simple, one daily packet approach, which is particularly helpful to seniors,
caregivers, chronically ill, and individuals with special needs among others.
"Our forward thinking
partnership with The Health Depot Pharmacy creates unprecedented access to a
seamless virtual care experience. Canadians need medical care and medications
in ways that accommodate their life circumstances", Ali Mohamed, CEO of
Lyte Medical says. "Lyte Medical's virtual platform allows patients to
speak to a doctor from the comfort of their own home and obtain their
prescribed medications and health products online from The Health Depot
Pharmacy, next day for free anywhere in Ontario with direct to door
delivery."
Lyte Medical's patient friendly
website makes connecting with a physician simple and easy. Lyte's comprehensive
services include primary care, specialist referrals, mental health support,
chronic pain treatment, and acute care. Patients will no longer have to take a
day off from work, make childcare arrangements, or wait in line for their
prescriptions, and for those living in rural areas, or vacationing at the
cottage, The Health Depot and Lyte Medical will bring healthcare to Canadians
at home, wherever that may be.
IM
Cannabis Corp. (CSE:
IMCC), a multi-country operator ("MCO") in the
medical cannabis sector with operations in Israel and across Europe, announced that
its German subsidiary, Adjupharm GmbH, has received a definitive purchase
commitment of medical cannabis over the next twelve months from Zur Rose Pharma
GmbH, an established distributor in Germany. This is the Company's fourth
definitive purchase commitment with a distributor in Germany and advances IMC's
strategy of creating a network of distribution partnerships to maximize
penetration of IMC-branded products.
"We have now signed our fourth
sales agreement with a binding purchase commitment. More importantly, we have
added Zur Rose Pharma GmbH as a key partner, a well-established and reputable
pharmaceutical service provider and
wholesaler that bolsters our ability to provide quality medical cannabis
products across the large and dynamic German market. As we continue to add
trusted partners to our MCO network, we firmly believe that we have created a
strong foundation to become the preeminent brand in international medical
cannabis," said Oren Shuster, CEO of IMC.
"The momentum IMC has
established within the German market is indicative of strong demand and
favourable industry fundamentals for medical cannabis. With the launch of the
IMC brand in Germany in Q3 2020, we have been deploying our sales teams to
further physician education across the country and build our brand's reputation
as a reliable provider of top quality medical cannabis to patients, pharmacists
and physicians," added Richard Balla, CEO of Adjupharm.
Through its EU-GMP certified
subsidiary, Adjupharm, the Company has entered into a three-year sales
agreement with the medical cannabis distributor Zur Rose Pharma GmbH in
Germany. This distributor has entered into a purchase commitment under its
sales agreement.
IMC has also previously announced
that Focus Medical Herbs Ltd. has signed six binding sales agreements for the
distribution of IMC-branded medical cannabis products in Israel. Total
consolidated revenue from all binding sales agreements in Israel is expected to
be $193.5 million with an expected gross margin of 50%. A total of 33,075kg of
medical cannabis will be delivered in Israel between Q2 2020 and 2023, and
3,000kg of medical cannabis under the sales agreements is expected to reach
pharmacies in 2020.
Global
Trac Solutions, Inc. (OTC:
PSYC) announced the 2nd
monthly release and distribution of the July edition of its Microdose Monthly
newsletter, which features three articles that provide an overview of Kevin
O’Leary’s investment participation with MindMed, a review of Gwyneth Paltrow’s
Goop Lab on Netflix, and an exclusive one-on-one interview with Chi Psilocybin,
a prominent voice for the psychedelic reform movement and owner of Truffles
Therapy in Amsterdam.
The interview with Chi, amply titled
“A Servant of the Mushroom Kingdom,” is an in-depth look at a personal journey
and discovery of the benefits associated with a life-long affinity for
psychedelics and finding life’s passion and purpose. On a trip to Thailand, Chi
met his future wife and co-founder of their company, Truffles Therapy, a
psilocybin retreat that has become his life’s work and has hosted many hundreds
of “journeyers” from all over the world. Chi believes that everyone should have
the opportunity to experience the magic of mushrooms.
David Flores, Global CEO, said, “I
would like to personally thank Chi for taking the time to share his unique and
fascinating story with us and for the voice he lends to the psychedelic reform
movement taking place across the globe. Chi is playing a vital role in the
industry’s continued emergence into society’s mainstream, which is showing
great promise through clinical studies for treating debilitating mental health conditions,
in addition to improving quality of life for millions across the globe. I
believe that our subscribers are really going to enjoy this month’s latest
newsletter written by Mr. Kent Sligh, Global’s Creative Content Director.
Furthermore, I look forward to developing our network of industry leaders and
advocates and exploring opportunities throughout this process to establish some
of the strategic partnerships that will in time contribute to our emergence as
an industry leader for news and information.”
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Contact Investorideas.com
800
665 0411
